Testing antibiotic dose levels for MAC lung infection
Part of Infections clinical trials.
This trial studies how much medicine is needed (based on lab results) to treat MAC lung disease, an infection in the lungs. If you already have MAC and are receiving the recommended core antibiotics, your care may help researchers link treatment details to lab measurements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lab-confirmed MAC lung infection (culture-positive)
- You are being treated for MAC at Shanghai Pulmonary Hospital
- Your MAC treatment includes the core drugs: a macrolide, rifamycin, and ethambutol at standard or higher recommended doses
- You can sign a written informed consent form
- You are not pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a single dose of the BCG vaccine (a live vaccine used for TB) can help the immune system fight MAC lung disease. Participants must not be on MAC treatment now, but may start it during the study if needed.
This trial studies whether inhaling hypertonic (very salty) saline helps treat nodular-bronchiectatic lung disease caused by Mycobacterium avium complex (MAC). It may help reduce ongoing infection and symptoms if you have the right type of MAC lung pattern and have not recently started the usual MAC treatments.
This trial tests if giving a medication (colistin) both through an IV and as a mist you breathe in works better for lung infections caused by bacteria that are hard to treat with standard antibiotics. It may help patients who have these tough bacteria and are in the hospital.
This trial tests whether a shorter course of antibiotics works for people with a specific type of lung infection caused by Mycobacterium avium complex (MAC). It aims to find a treatment that is just as effective but easier to complete.
This study follows people with a newly diagnosed MAC lung infection (a specific type of mycobacterial disease) and tests how they do on the standard three-drug treatment plan. It may help researchers better understand outcomes and safety for this condition.
This trial tests whether the drug Contezolid can quickly kill the bacteria that cause MAC lung disease, a type of lung infection. It is for people who have not been treated for this infection in the last 3 months.
Hear when a new Gram-Positive Bacterial Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.